High Prevalence of Chronic Kidney Disease Among People Living with Hypertension in Rural Sierra Leone: A Cross-Sectional Study

Chiyembekezo Kachimanga (1,2)
Anu Jegede Williams (3)
Musa Bangura (1)
Marta Lado (4)
Sahr Kanawa (5)
Daniel Lavallie (5)
Michael Mhango (1)
Haja Isatta Wurie (6)
Marta Patiño Rodriguez (1)

1Partners in Health Sierra Leone, Koidu City, Sierra Leone; 2Partners in Health Malawi, Neno, Malawi; 3Central Public Health Reference Laboratory, Ministry of Health and Sanitation, Freetown, Sierra Leone; 4World Health Organization, Geneva, Switzerland; 5Koidu Government Hospital, Ministry of Health and Sanitation, Koidu City, Sierra Leone; 6Laboratory Science Unit, College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown, Sierra Leone

Introduction: Currently, there are no data on prevalence and associated risk factors of chronic kidney disease (CKD) among patients with hypertension in rural Sierra Leone.

Purpose: To estimate the prevalence and associated risk factors of CKD in rural Sierra Leone.

Patients and Methods: A cross-sectional study of hypertension patients aged between 18 and 75 years attending a non-communicable disease clinic at Koidu Government Hospital, Kono District, Sierra Leone was conducted between February and December 2020. Using systematic random sampling, a structured questionnaire, which comprised of questions on social demographic characteristics and past and current clinical history, was administered followed by measurement of creatinine and urinary protein and glucose. Estimated glomerular filtration rate (eGFR) was estimated using CKD-epidemiology formula without race as a factor. Baseline eGFR between 60–89 min/mL/1.73m² and <60 min/mL/1.73m² defined reduced eGFR and renal impairment, respectively. Estimated GFR less than 60 min/mL/1.73m² measured two times at least 3 months apart was used to define CKD.

Results: Ninety-six percent (n = 304) patients out of 317 patients were included in the study. Among all included patients, only 3.9% (n = 12) had eGFR of 90 min/mL/1.73m² and above. The prevalence of renal impairment and CKD was 52% (158/304, CI 46.2–57.7) and 29.9% (91/304, CI 24.8–34.5), respectively. In adjusted logistic regression analysis, currently taking herbal medications as treatment of hypertension (OR 4.11 (CI 1.14–14.80), p = 0.03) and being overweight and/or obese (OR 2.16 (CI 1.24–3.78), p < 0.001) was associated with CKD. Additionally, receiving some education was associated with a 48% (OR 0.52 (CI 0.29–0.91), p = 0.02) reduced likelihood of CKD.

Conclusion: The prevalence of renal impairment and CKD is high among hypertensive patients in rural Sierra Leone. CKD was associated with current history of taking herbal medications and being overweight and/or obese. Additionally, CKD was associated with reduced likelihood in patients who received some education.

Keywords: hypertension, non-communicable diseases, CKD, renal impairment, screening, Sierra Leone

Introduction

Chronic kidney disease (CKD) is one of the diseases with high morbidity and mortality worldwide.¹ In 2017 alone, over 697 million new cases were reported and 1.2 million people died due to CKD worldwide.² CKD was the 10th most common cause of death in 2020, and by 2040, CKD will be the fifth leading cause of years of life lost worldwide.³,⁴ Low- and middle-income countries have disproportionately higher...
burden of CKD than high-income countries.\textsuperscript{5,6} The higher burden of CKD in low- and middle-income countries is mainly as a result of high CKD prevalence accompanied by low CKD awareness, epidemiological transition with a rising burden of NCDs, and lack of policies and organized health systems aimed at addressing CKD burden.\textsuperscript{7,8}

Chronic kidney disease burden is higher among people living with other non-communicable diseases (NCDs) like hypertension.\textsuperscript{9-11} For example, the burden of CKD among hypertensive patients in Africa is reported at 35.6\% by one recent study, twice as high as the prevalence in the general population.\textsuperscript{12} Hypertension is an independent risk factor for CKD and quickens the progression of CKD to end-stage renal disease (ESRD).\textsuperscript{13} Screening, early identification of CKD, subsequent management of CKD and control of hypertension is essential for reducing morbidity and mortality in hypertension patients.\textsuperscript{14}

Management of CKD in general, and CKD in hypertensive patients specifically, is a challenge in low- and middle-income settings. In these settings, CKD screening is not routinely offered to patients with hypertension due to unavailability of screening tests, lack of organized systems for management of hypertension and other NCDs and limited funding for NCD care.\textsuperscript{7} Additionally, lack of skilled staff to provide care, high cost of managing CKD, lack of infrastructure and absence of CKD in NCD policies and strategies contribute to challenges in managing CKD.\textsuperscript{8,15} Dialysis and renal replacement therapy is frequently not available, hence patients with ESRD commonly have no access to these treatment modalities.\textsuperscript{15-18}

As in many low and middle income countries, Sierra Leone is estimated to have a high burden of NCDs.\textsuperscript{19} In 2016, NCDs contributed to 33\% of all deaths.\textsuperscript{20} Estimates by recent studies have shown that the prevalence of hypertension in people over 20 years of age is over 20\% in Sierra Leone.\textsuperscript{21-23} Although data is extremely limited, Global Burden of Disease estimates over half a million cases of CKD in 2017.\textsuperscript{2} With evidence of hypertension as one of the strongest risk factor for CKD, management of hypertension should therefore include routine screening and treatment of CKD in Sierra Leone.\textsuperscript{24,25}

Despite the inclusion of screening and treatment of hypertension at regional and district hospitals in Sierra Leone’s package of essential health care, screening and management of CKD is not included in this package of care.\textsuperscript{26,27} As far as we know, there is no published data on the prevalence of CKD in rural Sierra Leone to date. Currently, there is no public dialysis unit and renal replacement therapy is not available. As far as we are aware, only one private facility in capital city of Sierra Leone, Freetown, offers dialysis services and the cost is prohibitive for many patients with CKD. Therefore, early screening and management of CKD patients presents a unique opportunity to identify CKD patients and start early management to slow the progression to ESRD. CKD screening, which includes the measurements of creatinine, is feasible and relatively cheaper in low and middle-income countries.\textsuperscript{6,28}

This study describes the prevalence and associated factors of CKD among hypertension patients in rural Sierra Leone. As far as we are aware, this is the first study to investigate CKD prevalence and provide evidence on the importance of screening for CKD in Sierra Leone.

**Materials and Methods**

**Setting and Study Type**

This is a cross-sectional study conducted at Koidu Government Hospital (KGH) in Kono District, Eastern Sierra Leone. Koidu Government Hospital, a Ministry of Health and Sanitation (MOHS) owned facility, is a secondary-level facility serving a catchment area of over half a million people and over 90 primary care facilities.\textsuperscript{29} This 200-bed hospital offers in-patient services and outpatient services as well as other ancillary services which includes pharmacy, radiology and laboratory. At the hospital, some services are supported by a non-governmental organization called Partners In Health (PIH) Sierra Leone. In Kono district, 67\% of the population lives in rural areas, and mining is the main source of income.\textsuperscript{30} The study was conducted between February and December 2020.

**Study Participants**

The study included hypertensive patients receiving NCD services at KGH NCD clinic. KGH NCD clinic is an integrated outpatient clinic for the chronic management of patients with hypertension, diabetes, chronic heart disease, CKD, and other NCDs. It was established in February 2018, initially managing patients with hypertension and diabetes, before integrating with other NCDs in early 2019. In response to the high burden of hepatitis B, the clinic incorporated patients with complications of hepatitis B virus in its cohort in mid-2019.\textsuperscript{31-33} The clinic is run by doctors, mid-level providers (known as Community Health Officers [CHOs]) and nurses. In
general, doctors manage patients with severe NCDs, CHOs manage non-severe NCD patients and nurses manage stable patients. Despite NCD care in Sierra Leone not included in the free health-care category, NCD services at KGH, including laboratory, pharmacy and radiology services, are provided free of charge with support from PIH.\textsuperscript{34} For hypertension management in the NCD clinic, patients were enrolled in care if they had been diagnosed and are on medication for hypertension or if they are screened on the clinic day. During clinic screening, patients were enrolled if they had two blood pressure measurements $\geq$140/90 mmHg measured at least two minutes apart. We have recently described the enrollment and outcomes of hypertension patients in the first year of the clinic.\textsuperscript{35}

Inclusion and Exclusion Criteria and Sample Size Calculations
In this study, we included hypertensive patients aged between 18 and 75 years receiving care at KGH NCD clinic. We excluded patients outside this age category, with pre-existing CKD, and patients with other diagnosis other than hypertension. Among the eligible hypertensive patients, we included patients that were able to give informed consent. We aimed to interview a minimum of 303 hypertensive patients. This was calculated based on CKD prevalence of 35.6\% among hypertension patients in Africa, cumulative cohort of 2007 hypertension patients at KGH NCD clinic as of December 31, 2019 and a 5\% margin of error.\textsuperscript{12} We adjusted the sample size to 318 to account for a 5\% non-response rate.

Data Collection Tools and Sampling
We developed a structured questionnaire consisting of social-demographic characteristics, medical history, family history and current management based on risk factors of CKD identified from relevant literature.\textsuperscript{36–38} The questionnaire was administered in Krio, the commonest language spoken in Sierra Leone. Initially, the questionnaire was drafted in English. This was forward translated to Krio and backward translated to English by native Krio and English speakers to ensure no losses in translation. Finally, we pre-tested the questionnaire to ten patients to identify problematic questions, reduce measurements error and determine the best order of questions.

We used systematic random sampling to identify eligible patients on a clinic day. Initially, we randomly chose the first eligible patient to be enrolled between first and fifth patient using a random number generator. After the first patient eligible patients was identified, we enrolled every third patient.

Upon identification and enrollment, each eligible patient was interviewed by trained interviewer either before or after clinical consultation. The interview lasted at least 30 minutes. Anthropometric measurements and clinical information was obtained directly from patients’ charts. The patients were then sent to KGH laboratory for collection of whole blood and urine samples for creatinine and urinary dipstick. For patients that required follow-up, we collected their contact details and were called using telephone for repeat tests after at-least 3 months from the enrollment date.

Measurements and Variables
The dependent variable was CKD. We used Kidney Disease: Improving Global Outcomes (KDIGO) definition of CKD defined as persistent estimated glomerular filtration rate (eGFR) of less than 60 mL/min/1.73m$^2$ for more than 3 months.\textsuperscript{39} We used CKD epidemiology (CKD-Epi) formula without race to calculate eGFR. We used the CKD-Epi formula without race as some studies have shown this to be the better formula for African populations.\textsuperscript{40–42} Estimated GFR of less than 60 mL/min/1.73m$^2$ on one occasion was regarded as renal impairment. Estimated GFR was categorized based on KDIGO classification.\textsuperscript{39} Independent variables collected included:

1. Social-demographic characteristics: age (in years), gender (male or female), education level (never educated or some education), occupation (none, employed, farmer) and marital status (not married or married/cohabiting).

2. Medical history: years living with hypertension (0 to 2 years and over 2 years), years enrolled in the NCD clinic due to hypertension (Less than 12 months, 12 or more months), family history of hypertension (no, yes, I do not know), family history of CKD (no, yes, I do not know), history of smoking (yes or no), current or past alcohol drinking (yes or no), history of co-morbidities (diabetes, heart failure, HIV, stroke), intake of non-prescribed medications for hypertension (yes or no), past history of herbal medication used to treat hypertension (yes or no), current use of herbal medication for hypertension (yes or no), use of intake non-steroidal
anti-inflammatory drugs (NSAIDs) (yes, no, or do not know) and addition of salt in diet (yes or no).

3. Clinical observation and measurements. We used the patient charts to obtain the following measurements:

a. The number of antihypertensive medications prescribed and document if Angiotensin Converting Enzyme (ACE) inhibitors and NSAIDs were prescribed on the current clinic visit.

b. Body Mass Index (BMI). We calculated BMI based on current weight (in kilograms) and last known height (in meters). BMI was categorized as normal (18.5<25 kg/m²), underweight (below 18.5 kg/m²), overweight (25.0<30 kg/m²) and obesity (30 kg/m² and above) as defined by World Health Organization.43

c. Most recent systolic blood pressure (mmHg) and diastolic blood pressure (mmHg). Based on the clinical guidelines in use at the time, hypertension was classified as follows: normal/controlled (<140 and <90 mmHg), grade 1 (140–159 and/or 90–99 mmHg), grade 2 (160–179 and/or 100–109 mmHg) and grade 3 (≥180 and/or ≥110 mmHg).

d. Most recent fasting blood glucose (in mg/dl).

The above variables were routinely performed and documented in medical charts by nurses, and/or CHOs and Doctors and were protocol based.35 Additionally, we collected the following laboratory tests performed at the hospital laboratory by trained technicians:

(a) Creatinine (umol/l): A trained phlebotomist collected at least 3 millimeters of whole blood using aseptic technique for the measurement of creatinine. Creatinine was measured by HumaLyzer 3000 photometer by HUMAN Diagnostic Worldwide.44 The photometer uses creatinine liquid color for humalyzer 3000 to measure creatinine using kinetic and endpoint method (Jaffe).45

(b) Urine dipstick: At least 3 millimeters of fresh midstream urine was collected to measure urinary protein and glycosuria. Urine protein was categorized as negative and positive [combined +1, +2 and +3] and glycosuria was categorized as negative and positive (combined +1, +2 and +3).

Urine dipstick and creatinine were measured using the manufacturer’s standard operating protocols.

Data Management and Statistical Analysis
During study design phase, we planned to collect and analyze data on all variables of interest (see Supplementary Table 1). Since eGFR was used to measure CKD, we planned to exclude all participants without measurement of creatinine. For all other variables of interest, we aimed to analyze only the variables that have less than 5% of missing data, otherwise we planned to exclude variables with more than 5% missing data in our analysis.

During data collection phase, all data were collected in paper-based questionnaires and were entered into Microsoft Excel 2016. Data cleaning and analysis was performed using STATA version 15.

We described patient baseline characteristics using descriptive statistics. To allow comparison between patients with and without CKD, we performed bivariate analysis for baseline demographic, history and clinical characteristics. For categorical variables, Chi² test and Fisher’s exact test were used based on expected frequencies. For continuous variables, we used Student’s t-test and Wilcoxon rank-sum test for normally distributed and non-normally distributed variable respectively.

To show association between CKD and some of the variables, we performed logistic regression analysis. Firstly, we conducted univariate logistic regression analysis between CKD and single predictor variables. This was followed by analysis with single predictors variables, with the addition of age and gender as adjusting variables (see Supplementary Material Table 2 for test of variable interaction). P <0.05 signified statistical significance.

Ethical Approval and Consent to Participate
We obtained informed consent from all the eligible patients. Initially, the data was not anonymized as we needed to collect the samples for creatinine test for patients with eGFR <60 mL/min/1.73m². After the collection of repeat tests, we created an anonymized dataset which was used to perform data cleaning and analysis. The study received ethical approval from Office of Sierra Leone Ethics and Scientific Review Committee and was conducted in accordance with the Declaration of Helsinki.
Results
Baseline Characteristics of Hypertension Clients

We approached 317 eligible hypertension patients and included 304 (96%) in the final analysis (see Figure 1 and Table 1). Among the 304 patients, the majority of the patients had all the variables complete except for occupation (1.0% missing data), duration of care in the clinic (0.7% missing data), current number of antihypertensive drugs (0.3% missing data), median BMI/BMI category (2.6% missing data), proteinuria and glycosuria (0.7% missing data), and most recent diastolic blood pressure (0.3% missing data) (see Supplementary Table 1). We therefore included all the variables in our analysis as the 317 eligible patients

Figure 1 Hypertension patients screened for chronic kidney disease.
Notes: CKD was defined based on Kidney Disease: Improving Global Outcomes (KDIGO) guidelines: Persistent estimated glomerular filtration rate (eGFR) of less than 60 mL/min/1.73m² for more than 3 months. Estimated GFR of less than 60 mL/min/1.73m² on one occasion was regarded as renal impairment.
Abbreviations: CKD, chronic kidney disease; %, percentage.
**Table 1** Baseline Demographic and Clinical Characteristics of Hypertension Patients Included in the Study

| Variable                              | Total (n = 304) | No CKD (n = 213) | CKD (n = 91) | P-value* |
|---------------------------------------|----------------|-----------------|--------------|----------|
| Median age-Median, IQR                | 55 (48–63)     | 55 (46–62)      | 60 (50–65)   | 0.02     |
| Age category (years)-n,%              |                |                 |              | 0.07**   |
| 18–29                                 | 5 (1.6)        | 5 (2.3)         | 0 (0.0)      |          |
| 30–39                                 | 21 (6.9)       | 17 (8.0)        | 4 (4.4)      |          |
| 40–49                                 | 63 (20.7)      | 45 (21.1)       | 18 (19.8)    |          |
| 50–59                                 | 92 (30.3)      | 70 (32.9)       | 22 (24.2)    |          |
| 60 and above                          | 123 (40.5)     | 76 (35.7)       | 47 (51.6)    |          |
| Age less than 60                      | 181 (59.5)     | 137 (64.3)      | 44 (48.3)    | 0.009    |
| Age over 60                           | 123 (40.5)     | 76 (35.7)       | 47 (51.7)    |          |
| Gender- n,%                           |                |                 |              | 0.03     |
| Male                                  | 97 (31.9)      | 76 (35.7)       | 21 (23.1)    |          |
| Female                                | 207 (68.1)     | 137 (64.3)      | 70 (76.9)    |          |
| Educational level-n,%                 |                |                 |              | 0.001    |
| Never educated                        | 165 (54.3)     | 102 (47.9)      | 63 (69.2)    |          |
| Some education                        | 139 (45.7)     | 111 (52.1)      | 28 (30.8)    |          |
| Occupation-n,%                        |                |                 |              | 0.3      |
| None                                  | 114 (37.5)     | 75 (35.2)       | 39 (42.9)    |          |
| Employed                              | 132 (43.4)     | 93 (43.7)       | 39 (42.9)    |          |
| Farmer                                | 55 (18.1)      | 42 (19.7)       | 13 (14.2)    |          |
| Missing                               | 3 (1.0%)       | 3 (1.4)         | 0 (0.0)      |          |
| Marital status-n,%                    |                |                 |              | 0.24     |
| Not married                           | 102 (33.6)     | 67 (31.5)       | 35 (38.5)    |          |
| Married/cohabiting                    | 202 (66.4)     | 146 (68.5)      | 56 (61.5)    |          |
| Years since hypertension diagnosis-n,%|                |                 |              | 0.16     |
| 0–2years                              | 169 (55.6)     | 124 (58.2)      | 45 (49.4)    |          |
| Over 2 years                          | 135 (44.4)     | 89 (41.8)       | 46 (50.6)    |          |
| Duration in the clinic (Months)-n,%   |                |                 |              | 0.02     |
| Less than 12 months                   | 170 (55.9)     | 129 (60.6)      | 41 (45.1)    |          |
| More than 12 months                   | 132 (43.4)     | 84 (39.4)       | 48 (52.7)    |          |
| Missing                               | 2 (0.7)        | 0 (0.0)         | 2 (2.2)      |          |
| Family history of hypertension-n,%    |                |                 |              | 0.81     |
| No                                    | 81 (26.6)      | 59 (27.7)       | 22 (24.2)    |          |
| Yes                                   | 147 (48.4)     | 101 (47.4)      | 46 (50.5)    |          |
| Do not Know                           | 76 (25.0)      | 53 (24.9)       | 23 (25.3)    |          |

(Continued)
Table 1 (Continued).

| Variable                              | Total (n = 304) | No CKD (n = 213) | CKD (n = 91) | P-value* |
|---------------------------------------|----------------|-----------------|--------------|----------|
| Family history CKD-n, %               |                |                 |              |          |
| No                                    | 161 (53.0)     | 110 (51.6)      | 51 (56.0)    | 0.36**   |
| Yes                                   | 9 (3.0)        | 5 (2.4)         | 4 (4.4)      |          |
| Do not Know                           | 134 (44.0)     | 98 (46.0)       | 36 (39.6)    |          |
| History of smoking-n, %               |                |                 |              |          |
| No                                    | 199 (65.5)     | 137 (64.3)      | 62 (68.1)    | 0.52     |
| Yes                                   | 105 (34.5)     | 76 (35.7)       | 29 (31.9)    |          |
| History of alcohol intake-n, %        |                |                 |              |          |
| No                                    | 205 (67.4)     | 140 (65.7)      | 65 (71.4)    | 0.33     |
| Yes                                   | 99 (32.6)      | 73 (34.3)       | 26 (28.6)    |          |
| History of Diabetes-n, %              |                |                 |              |          |
| No                                    | 270 (88.8)     | 191 (89.7)      | 79 (86.8)    | 0.47     |
| Yes                                   | 34 (11.2)      | 22 (10.3)       | 12 (13.2)    |          |
| History of heart failure-n, %         |                |                 |              |          |
| No                                    | 295 (97.1)     | 207 (97.2)      | 88 (96.7)    | 0.79**   |
| Yes                                   | 8 (2.6)        | 5 (2.3)         | 3 (3.3)      |          |
| Do not Know                           | 1 (0.30)       | 1 (0.5)         | 0 (0.0)      |          |
| Living with HIV-n, %                  |                |                 |              |          |
| No                                    | 299 (98.4)     | 211 (99.1)      | 88 (96.7)    | 0.16**   |
| Yes                                   | 5 (1.6)        | 2 (0.9)         | 3 (3.3)      |          |
| History of previous stroke-n, %       |                |                 |              |          |
| No                                    | 281 (92.4)     | 196 (92.0)      | 85 (93.4)    | 0.66     |
| Yes                                   | 23 (7.6)       | 17 (8.0)        | 6 (6.6)      |          |
| Intake of non-prescribed medication for hypertension -n, % | | | | |
| No                                    | 250 (82.2)     | 175 (82.4)      | 75 (82.4)    | 0.96     |
| Yes                                   | 54 (17.8)      | 38 (17.6)       | 16 (17.6)    |          |
| Past Intake of herbal medications for hypertension-n, % | | | | |
| No                                    | 247 (81.2)     | 174 (81.7)      | 73 (80.2)    | 0.76     |
| Yes                                   | 57 (18.8)      | 39 (18.3)       | 18 (19.8)    |          |
| Current Intake of herbal medications for hypertension -n, % | | | | |
| No                                    | 293 (96.4)     | 209 (98.1)      | 84 (92.3)    | 0.02**   |
| Yes                                   | 11 (3.6)       | 4 (1.9)         | 7 (7.7)      |          |

(Continued)
Table 1 (Continued).

| Variable | Total (n = 304) | No CKD (n = 213) | CKD (n = 91) | P-value* |
|----------|----------------|-----------------|-------------|----------|
| No       | 145 (47.7)     | 97 (45.5)       | 48 (52.7)   | 0.18     |
| Yes      | 100 (32.9)     | 77 (36.2)       | 23 (25.3)   |          |
| Do not Know | 59 (19.4) | 39 (18.3)       | 20 (22.0)   |          |
| Normally add salt before eating-n,% | | | | |
| Never   | 79 (26.0)      | 53 (24.9)       | 26 (28.6)   | 0.5     |
| Eat salt | 225 (74.0)     | 160 (75.1)      | 65 (71.4)   |          |
| Current number of anti-hypertensive drugs –n,% | | | | |
| 1       | 20 (6.6)       | 12 (5.6)        | 8 (8.9)     | 0.52     |
| 2       | 201 (66.1)     | 144 (67.6)      | 57 (62.6)   |          |
| 3 or more | 82 (27.0) | 56 (26.3)       | 26 (28.5)   |          |
| Missing | 1 (0.3)        | 1 (0.5)         | 0 (0.0)     |          |
| Current use of ACE Inhibitors-n,% | | | | |
| No       | 199 (65.5)     | 141 (66.2)      | 58 (63.7)   | 0.68     |
| Yes      | 105 (34.5)     | 72 (33.8)       | 33 (36.3)   |          |
| Currently taking NSAIDs-n,% | | | | |
| No       | 261 (85.9)     | 182 (85.4)      | 79 (86.8)   | 0.75     |
| Yes      | 43 (14.1)      | 31 (14.6)       | 12 (13.2)   |          |
| Median BMI (kg/m²)-median, IQR | 26.2 (22.4–30.5) | 25.7 (21.9–30.1) | 28.0 (24.0–31.0) | 0.008c |
| BMI category (kg/m²)-n,% | | | | |
| Underweight (below 18.5 kg/m²) | 9 (3.0) | 7 (3.3) | 2 (2.2) | 0.02a |
| Normal (18.5–<25 kg/m²) | 114 (37.5) | 91 (42.7) | 23 (25.3) |          |
| Overweight (25.0–<30 kg/m²) | 88 (28.9) | 54 (25.4) | 34 (37.4) |          |
| Obesity (30.0 kg/m² and above) | 85 (28.0) | 56 (26.3) | 29 (31.9) |          |
| Missing | 8 (2.6)        | 5 (2.3)         | 3 (3.2)     |          |
| Most recent systolic blood pressure (mmHg)-Median, IQR | 158 (143–177) | 158 (143–177) | 158 (143–177) | 0.78c |
| Most recent diastolic blood pressure (mmHg)-Median, IQR | 99 (92–109) | 99 (93–109) | 98 (90–109) | 0.22c |
| Most recent blood glucose (mg/dl)-Median, IQR | 5.7 (4.9–7.2) | 5.7 (4.9–7.2) | 5.4 (4.8–6.8) | 0.21† |
| Hypertension grade-n,% | | | | |
| Normal (<140 and <90 mmHg) | 39 (12.8) | 26 (12.2) | 13 (14.3) | 0.88 |
| Grade 1 (140–159 and/or 90–99 mmHg) | 82 (27.0) | 57 (26.8) | 25 (27.4) |          |
| Grade 2 (160–179 and/or 100–109 mmHg) | 79 (26.0) | 58 (27.2) | 21 (23.1) |          |
| Grade 3 (≥180 and/or ≥110 mmHg) | 104 (34.2) | 72 (33.8) | 32 (35.2) |          |

Notes: *Chi² tests unless otherwise stated Fishers exact test, †Wilcoxon rank-sum test. Bold P-value less than 0.05.
Abbreviations: CKD, chronic kidney disease; IQR, interquartile range; %, percentage; NSAIDs, non-steroidal anti-inflammatory drugs; n, number; BMI, body mass index; ACE, angiotensin converting enzyme.
missing data in all the variables were below the 5% threshold.

The median age of eligible patients was 55 years (IQR 48–63 years) and over two-thirds were females (68.1%, n = 207). The median BMI was 26.2 kg/m$^2$ (IQR 22.4–30.5 kg/m$^2$) with over half of the patients being overweight or obese. Slightly over half of the patients had never received any education, two-thirds were married/cohabiting and most were either farmers or were employed.

Over half of the clients (n = 169, 55.6%) had been diagnosed with hypertension within two years prior to the inclusion into this study and had been enrolled in the clinic for less than 12 months (55.9%, n = 170). Among existing comorbidities, 11.2% (n = 34), 7.6% (n = 23), 2.6% (n = 8) and 1.6% (n = 5) had been diagnosed with diabetes, stroke, heart failure and HIV, respectively. The median systolic blood pressure and diastolic blood pressure were 158 mmHg (IQR 143–177) and 99 mmHg (IQR 92–109), respectively. About 27% (n = 82) and 34.5% (n = 105) were on three or more antihypertensive drugs and ACE inhibitors, respectively.

**Creatinine, Renal Impairment and Chronic Kidney Disease**

The mean serum creatinine was 105.5 umol/l (standard deviation 35.2) and mean baseline eGFR was 60.6 min/mL/1.73m$^2$. 12.5% (n = 38) and 4.3 (n = 13) had proteinuria of at least 1+ and glycosuria of at least 1+, respectively (Tables 2 and 3).

| Laboratory Measurements | Total (n = 304) | No CKD (n = 213) | CKD (n = 91) | p-value$^*$ |
|--------------------------|----------------|------------------|-------------|------------|
| Serum Creatinine (µmol/l)-Mean, SD | 105.5, 35.2 | 100.0, 34.3 | 118, 33.9 | <0.001\(^d\) |
| Proteinuria-n,% | | | | |
| Negative | 264 (86.8) | 189 (88.7) | 75 (82.4) | 0.31\(^h\) |
| 1+ or more | 38 (12.5) | 23 (10.8) | 15 (16.5) | |
| Missing | 2 (0.7) | 1 (0.5) | 1 (1.1) | |
| Glycosuria-n,% | | | | |
| Negative | 289 (95.1) | 203 (95.3) | 86 (94.5) | 0.78\(^h\) |
| 1+ or more | 13 (4.3) | 9 (4.2) | 4 (4.4) | |
| Missing | 2 (0.6) | 1 (0.5) | 1 (1.1) | |

Notes: $^a$Chi square test unless stated $^b$Fishers exact test, $^c$Student’s t test, Bold P-value less than 0.05 SD standard deviation. CKD was defined based on Kidney Disease: Improving Global Outcomes (KDIGO) guidelines: Persistent estimated glomerular filtration rate (eGFR) of less than 60 mL/min/1.73m$^2$ for more than 3 months. As such, only 111 patients (out of 158) with renal impairment had a repeat creatinine test and hence were included in the calculation of CKD. Estimated GFR of less than 60 mL/min/1.73m$^2$ on one occasion was regarded as renal impairment.

**Abbreviations:** CKD, chronic kidney disease; SD, standard deviation.

Based on KDIGO classification of eGFR, only 3.9% (n = 12) were within normal eGFR and the rest of the patients were within G2-G5 categories. The prevalence of renal impairment was 52% (158/304, CI 46.2–57.7%).

On follow-up of the patients, we were able to successfully re-test 111 patients (representing 70%) of 158 patients with renal impairment after at least 3 months (Table 3). Among this cohort, only 20 patients had eGFR which was 60 min/mL/1.73m$^2$ and above. The prevalence of CKD was 29.9% (91/304, CI 24.8–34.5%).

There were differences between patients with and without CKD on baseline characteristics. The median age for

| Estimated Glomerular Filtration Rate (min/mL/1.73m$^2$) | N (%) |
|------------------------------------------------------|-------|
| Mean eGFR                                             | 60.6 (SD 15.7, range 12.7–128.2) |
| Normal eGFR (90 and above)                            | 12 (3.9) |
| G2 60–89                                             | 134 (44.1) |
| G3 $a$ 59–45                                        | 122 (40.1) |
| G3$b$ 44–30                                         | 29 (9.5) |
| G4 29–15                                           | 6 (2.0) |
| G5 <15                                              | 1 (0.3) |

**Abbreviations:** eGFR, estimated glomerular filtration rate; KDIGO, Kidney Disease: Improving Global Outcomes; SD, standard deviation.
patients with CKD was 60 years (IQR 50–65 years) while median age was 55 years (IQR 46–62 years) in patients without CKD. The prevalence of CKD increased with age, with patients aged 60 years and above having the highest rates of CKD (51.7%, n = 47) (Figure 2). Additionally, CKD was more common in females than males (76.9% vs 23.1%, p = 0.03), was common in patients who are illiterate than patients who are literate (69.2% vs 30.8%, p = 0.01), and common in patients who were enrolled for over 12 months in clinic that less than 12 months in the clinic (52.7% vs 45.1%, p = 0.02). Furthermore, CKD was common in patients with a higher BMI. There were no statistically significant differences between patients who admitted taking herbal medication in the past, but significant differences were observed in patients who were taking herbal medication at the time of the study. In this cohort, only 12.8% (n = 39) of the patients had good hypertension control. CKD was lowest in patients with good control (14.3%) but increased to 35.2% in patients with grade 3 hypertension (Figure 3).

Factors Associated with Chronic Kidney Disease

Table 4 summarizes unadjusted and adjusted odds ratio of factors associated with CKD. Before adjusting for age and gender, there were statistically significant associations between CKD and advanced age, female gender, education level, longer duration in the clinic, current intake of herbal medication for hypertension treatment, and being overweight and/or obese. Age and female gender were associated with higher odds of CKD (OR 1.03 (CI 1.01–1.05) and 1.85 (CI 1.05–3.25)) respectively. Adjusting for age and gender, only education level, current intake of herbal medication for hypertension treatment, and being overweight and/or obese were associated with CKD. Adjusting for age and gender, receiving some education was associated with a 48% reduction in the likelihood of CKD (OR 0.52 (CI 0.29–0.91), p = 0.02). Currently taking herbal medications as treatment of hypertension was associated with four times the odds of having CKD (OR 4.11 (CI 1.14–14.80), p = 0.03). Finally, patients who were overweight and/or obese had more than two times the odds of having CKD (OR 2.16 (1.24–3.78), p = <0.001) in comparison to patient who had BMI less than 25 kg/m².

Discussion

Sierra Leone national NCD and Injury poverty commission, which was established in early 2018 by MOHS and its findings were published in late 2020, identified priority NCDs that required to be urgently addressed in order to reduce the morbidity and mortality of NCDs in Sierra Leone. Chronic kidney disease due to hypertension was included among 43 priority NCDs and injuries. Furthermore, the commission prioritized treatment of hypertension among CKD patients beginning from primary healthcare facilities. Addressing morbidity and mortality of CKD due to hypertension goes beyond policy and strategies and requires understanding the prevalence and associated factors of CKD. This is the first study to specifically investigate the burden of CKD in rural Sierra Leone.
### Table 4 Associated Factors of Chronic Kidney Disease

| Clinical History                          | Unadjusted Odds Ratio | P-value | Adjusted Odds Ratio* | P-value |
|-------------------------------------------|-----------------------|---------|----------------------|---------|
| Median age                                | 1.03 (1.01–1.05)      | 0.01    | -                    | -       |
| Age category                              |                       |         |                      |         |
| Less than 60 years                        | Ref                   | 0.01    | -                    | -       |
| 60 years and above                        | 1.92 (1.17–3.17)      | -       | -                    | -       |
| Gender                                    |                       |         |                      |         |
| Male                                      | Ref                   | -       | -                    | -       |
| Female                                    | 1.85 (1.05–3.25)      | 0.03    | -                    | -       |
| Education level                           |                       |         |                      |         |
| No education                              | Ref                   | Ref     | Ref                  | Ref     |
| Some education                            | 0.41 (0.24–0.69)      | 0.001   | 0.52 (0.29–0.91)     | 0.02    |
| Occupation                                |                       |         |                      |         |
| Not employed                              | Ref                   | Ref     | Ref                  | Ref     |
| Employed                                  | 0.81 (0.47–1.38)      | 0.43    | 1.22 (0.67–2.22)     | 0.52    |
| Farmer                                    | 0.60 (0.29–1.24)      | 0.17    | 0.62 (0.29–1.31)     | 0.21    |
| Marital status                            |                       |         |                      |         |
| Not married                               | Ref                   | Ref     | Ref                  | Ref     |
| Married/cohabiting                        | 0.73 (0.44–1.23)      | 0.24    | 1.15 (0.64–2.06)     | 0.64    |
| Years since hypertension diagnosis        |                       |         |                      |         |
| 0–2 years                                 | Ref                   | Ref     | Ref                  | Ref     |
| Over 2 years                              | 1.42 (0.87–2.33)      | 0.16    | 1.44 (0.87–2.39)     | 0.16    |
| Duration in the clinic                    |                       |         |                      |         |
| Less than 12 months                       | Ref                   | Ref     | Ref                  | Ref     |
| 12 months and above                       | 1.80 (1.09–2.96)      | 0.02    | 1.62 (0.97–2.70)     | 0.07    |
| Family History of hypertension            |                       |         |                      |         |
| No                                        | Ref                   | Ref     | Ref                  | Ref     |
| Yes                                       | 1.22 (0.67–2.23)      | 0.51    | 1.45 (0.77–2.72)     | 0.25    |
| Family History of Chronic Kidney Disease  |                       |         |                      |         |
| No                                        | Ref                   | Ref     | Ref                  | Ref     |
| Yes                                       | 1.73 (0.44–6.70)      | 0.43    | 2.38 (0.56–10.12)    | 0.24    |
| History of Smoking                        |                       |         |                      |         |
| No                                        | Ref                   | Ref     | Ref                  | Ref     |
| Yes                                       | 0.84 (0.50–1.42)      | 0.52    | 0.99 (0.56–1.74)     | 0.98    |

(Continued)
Table 4 (Continued).

| Clinical History                  | Unadjusted Odds Ratio | P-value | Adjusted Odds Ratio | P-value |
|-----------------------------------|-----------------------|---------|---------------------|---------|
| No                                | Ref                   | Ref     |                     |         |
| Yes                               | 0.77 (0.45–1.31)      | 0.33    | 0.95 (0.53–1.73)    | 0.88    |
| History of Diabetes               |                       |         |                     |         |
| No                                | Ref                   | Ref     |                     |         |
| Yes                               | 1.32 (0.62–2.79)      | 0.47    | 1.36 (0.63–2.92)    | 0.44    |
| History of heart disease          |                       |         |                     |         |
| No                                | Ref                   | Ref     |                     |         |
| Yes                               | 1.41 (0.33–6.03)      | 0.64    | 1.74 (0.40–7.63)    | 0.46    |
| Living with HIV                   |                       |         |                     |         |
| No                                | Ref                   | Ref     |                     |         |
| Yes                               | 3.60 (0.59–21.90)     | 0.17    | 4.46 (0.70–28.73)   | 0.11    |
| History of stroke                 |                       |         |                     |         |
| No                                | Ref                   | Ref     |                     |         |
| Yes                               | 0.81 (0.31–2.14)      | 0.66    | 0.70 (0.26–1.88)    | 0.48    |
| Intake of non-prescribed medication for hypertension | | | | |
| No                                | Ref                   | Ref     |                     |         |
| Yes                               | 0.98 (0.52–1.87)      | 0.96    | 0.95 (0.49–1.85)    | 0.88    |
| Past Intake of herbal medications for hypertension | | | | |
| No                                | Ref                   | Ref     |                     |         |
| Yes                               | 1.10 (0.39–2.05)      | 0.76    | 1.01 (0.53–1.92)    | 0.98    |
| Current Intake of herbal medications for hypertension | | | | |
| No                                | Ref                   | Ref     |                     |         |
| Yes                               | 4.35 (1.24–15.26)     | 0.02    | 4.11 (1.14–14.80)   | 0.03    |
| Use of intake Anti-inflammatory drugs | | | | |
| No                                | Ref                   | Ref     |                     |         |
| Yes                               | 0.60 (0.34–1.08)      | 0.09    | 0.61 (0.34–1.10)    | 0.1     |
| Normally add salt before eating   |                       |         |                     |         |
| No                                | Ref                   | Ref     |                     |         |
| Yes                               | 0.60 (0.34–1.08)      | 0.09    | 0.83 (0.47–1.46)    | 0.52    |
| Current number of anti-hypertensive Drugs | | | | |
| 1                                 | Ref                   | Ref     |                     |         |
| 2                                 | 0.59 (0.23–1.53)      | 0.28    | 0.53 (0.20–1.42)    | 0.21    |
| 3 or more drugs                   | 0.70 (0.23–1.53)      | 0.28    | 0.68 (0.24–1.93)    | 0.47    |

(Continued)
Screening for CKD allows for early identification of reduced GFR, renal impairment and CKD. This enables early management of these patients to prevent progression to ESRD. Additionally, screening helps to increase awareness of CKD, as many patients in limited resource settings are not aware if they have been screened and/or they have CKD. Finally, screening ensures avoidance of using medication that may lead to worsening of the function of the kidneys. In this study, 96% and 52% of the patients had a baseline eGFR within stage G2-G5 and G3-G5 eGFR categories respectively. This shows the value of screening as reduced eGFR can be identified early. As part of the protocol, patients in stage G3-G5 eGFR categories were contacted by phone to let them know the outcome of their tests. Additionally, all included patients received an explanation of their results during their clinic visits. This may have increased their awareness of reduced eGFR, renal impairment and CKD.

As the first study conducted in Sierra Leone, there is lack comparison of our study with other settings in Sierra Leone. However, CKD rates and risk factors can be compared with other countries in Africa.

Table 4 (Continued).

| Clinical History | Unadjusted Odds Ratio | P-value | Adjusted Odds Ratio* | P-value |
|------------------|-----------------------|---------|----------------------|---------|
| **Current use of ACE Inhibitors** | | | |
| No | Ref | Ref | | |
| Yes | 1.11 (0.67–1.86) | 0.68 | 1.10 (0.64–1.89) | 0.72 |
| **Currently taking NSAIDs** | | | |
| No | Ref | Ref | | |
| Yes | 0.89 (0.43–1.82) | 0.75 | 0.90 (0.42–1.89) | 0.77 |
| **BMI Category** | | | |
| Less than 25 | Ref | Ref | | |
| Overweight/obesity | 2.24 (1.31–3.84) | <0.001 | 2.16 (1.24–3.78) | <0.001 |
| **Most recent systolic blood pressure** | | | |
| 1.00 (0.99–1.01) | 0.72 | | 1.00 (0.99–1.01) | 0.59 |
| **Most recent diastolic blood pressure** | | | |
| 0.99 (0.97–1.01) | 0.27 | | 1.0 (0.98–1.01) | 0.72 |
| **Most recent blood glucose** | | | |
| 0.99 (0.92–1.08) | 0.9 | | 0.99 (0.91–1.07) | 0.80 |
| **Proteinuria** | | | |
| Negative | Ref | Ref | | |
| 1+ or more | 1.64 (0.81–3.32) | 0.17 | 1.69 (0.82–3.49) | 0.16 |
| **Glycosuria** | | | |
| Negative | Ref | Ref | | |
| 1+ or more | 1.05 (0.31–3.5) | 0.94 | 1.02 (0.29–3.56) | 0.97 |
| **Hypertension grade** | | | |
| Normal (<140 and <90 mmHg) | Ref | | | |
| Grade 1 (140–159 and/or 90–99 mmHg) | 0.88 (0.39–1.98) | 0.75 | 0.88 (0.38–2.02) | 0.76 |
| Grade 2 (160–179 and/or 100–109 mmHg) | 0.72 (0.31–1.66) | 0.45 | 0.74 (0.32–1.74) | 0.49 |
| Grade 3 (≥180 and/or ≥110 mmHg) | 0.89 (0.40–1.95) | 0.77 | 0.94 (0.42–2.12) | 0.89 |

Notes: *Adjusted by age, gender; bold P value less than 0.05.
Abbreviations: NSAIDs, non-steroidal anti-inflammatory drugs; ACE inhibitor, angiotensin converting enzyme; BMI, body mass index.
The high prevalence of CKD reported in this study is similar to findings reported among hypertension patients in other settings. For example, two recent reviews found the pooled CKD prevalence of 35.6% and 34% among hypertensive patients in Africa. A recent study has suggested that west African countries has higher rates of CKD due to hypertension than other regions in Africa. Most of the patients in this study had uncontrolled hypertension, although hypertension stage was not associated with CKD in logistic regression analysis. Lower rates of hypertension control has been reported in other settings, for example in Nigeria where only 39.7% of inpatients had optimal blood pressure control. Controlling hypertension is one of the strategies for slowing progression of CKD to ESRD. Moving forward, reasons for poor control should be identified and appropriate treatment should be instituted to ensure more patients have optimal blood pressure control.

Based on this study, plans are underway to include routine CKD screening, management and follow-up in our NCD clinic. This includes an annual CKD screening for patients that did not have CKD when we conducted the study. For the patients with CKD, enrollment in care and management, including for comorbidities, is essential to make sure we halt the progress to ESRD. Beyond Kono district, our findings warrant the development of a comprehensive program to screen, identify and manage CKD among hypertension patients in Sierra Leone. In the long term, there is a need for the development of a CKD registry to monitor the burden of the disease. Advanced treatment options for the management of CKD, including dialysis and renal replacement therapy, will also need to be available in Sierra Leone. As an extension, it is necessary to conduct similar studies in urban areas, among the general population and other high risk groups like diabetes mellitus.

This study has found that CKD is associated with advanced age, female gender, no formal education and being overweight/obese. This is consistent with findings of other studies in Africa. As CKD increases with age, where resources are limited, it will be prudent to start screening patients with advanced age first, before screening younger population. Although we did not explore why CKD is more likely to occur in female gender, we know that our sample was mainly female and this result may be due to selection bias. To address the challenge with overweight and obese patients, screening for obesity, counselling on good dietary habits and regularly exercising and other ways of reducing obesity should be included to the health education that is provided in KGH NCD clinics.

Current intake of herbal medication for treatment of hypertension was one of the factors associated with CKD, and other studies has also found similar association between taking herbal medications and CKD. Taking herbal medication may also be associated with acute kidney injury which may lead to CKD, interaction of herbal remedies with other medications and direct toxicity to the kidneys by some herbal medications. There is a need to explore further on the types of herbal medications and identify if these medications predispose hypertension patients to CKD. Additionally, patient education on the dangers of harmful herbal medication needs to be intensified.

We noted several limitations to our study. Most of our participants were females and over one third of the participants were unemployed. Due to this selection bias, further studies should be designed with equal gender representation and consider CKD screening in occupation settings to identify and enroll more males in the studies. Due to its cross-sectional design, our study could not show causality and temporal associations between CKD and associated risk factors. We used CKD-EPI as it has been shown to better predict eGFR in Africa. However, no study has validated CKD-EPI or other creatinine formulas in Sierra Leone population. Although we aimed to re-test all patients with renal impairment, we could not find all the patients. Additionally, we could not collect data on why these patients did not come to clinic for re-testing. However, we know the study was conducted during coronavirus-19 pandemic, and this may have impacted the utilization of health services by hypertension patient. Further studies can explore reasons why we could not reach all patients and develop strategies that can guarantee the re-testing of all patients. Finally, we only used reduced GFR to define CKD, and did not use albuminuria, albumin to creatinine ratio, 24-hour urinary albumin, and abnormalities of the kidneys identified by ultrasound or renal biopsy to define CKD. We used urine dipsticks, which are less sensitive to lower levels of proteinuria, due to unavailability of more sensitive tests. Our study may therefore have underestimated the prevalence of CKD in this patient population.

Despite the limitations, we know this is the first study in Sierra Leone and can be used to provide evidence on CKD screening among hypertension patients. To Increase rigor of the study, we forward and backward translated our
questionnaire tool and used systematic random sampling to recruit study participants. Finally, we also used two measurements of creatinine measured at least three months apart to confirm CKD.

### Conclusion

The prevalence of renal impairment and CKD is high among hypertensive patients in rural Sierra Leone. CKD was associated with advanced age, female gender, current history of taking herbal medications and with being overweight/obese. Additionally, receiving some education was associated with a 48% reduced likelihood of CKD. We recommend regular screening for CKD in Sierra Leone.

### Acknowledgments

We acknowledge many health-care workers that supported the development and implementation of NCD clinic in Kono including Joseph S. Gasimu, Bernadetta Makannah, Emmanuel Nyama and Thomas Bockarie. We also acknowledge the leadership of Koidu Government Hospital and Partners In Health Sierra Leone. Finally, we acknowledge all the patients that were part of the study.

### Disclosure

The authors report no conflicts of interest in this work.

### References

1. Ng JK, Li PK. Chronic kidney disease epidemic: how do we deal with it? *Nephrology*. 2018;23 Suppl 4:116–120. doi:10.1111/nep.13464

2. Bikbov B, Purcell CA, Levey AS, GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet*. 2020;395(10225):709–733. doi:10.1016/S0140-6736(20)30045-3

3. World Health Organization. The top 10 causes of death. Available from: https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death. Accessed September 8, 2021.

4. Foreman KJ, Marquez N, Dolgert A, et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016–40 for 250 countries and territories. *Lancet*. 2018;392(10159):2052–2090. doi:10.1016/S0140-6736(18)31694-5

5. Coresh J. Update on the Burden of CKD. *J Am Soc Nephrol*. 2017;28(4):1020–1022. doi:10.1681/asn.2016121374

6. Ameh OI, Ekrikpo UE, Kengne AP. Preventing CKD in low- and middle-income countries: a call for urgent action. *Kidney Int Rep*. 2020;5(3):255–262. doi:10.1016/j.ekir.2019.12.013

7. Chen A, Zou M, Young CA, et al. Disease burden of chronic kidney disease due to hypertension from 1990 to 2019: a global analysis. *Front Med*. 2021;8:690487. doi:10.3389/fmed.2021.690487

8. Ameh OI, Ekrikpo U, Bello A, Okpechi I. Current management strategies of chronic kidney disease in resource-limited countries. *Int J Nephrol Renovasc Dis*. 2020;13:239–251. doi:10.2147/ijnrd.S242255

9. Deng Y, Li N, Wu Y, et al. Global, regional, and national burden of diabetes-related chronic kidney disease from 1990 to 2019. *Front Endocrinol (Lausanne)*. 2021;12:672350. doi:10.3389/fendo.2021.672350

10. Murton M, Goff-Leggott D, Bobrowska A, et al. Burden of chronic kidney disease by KDIGO categories of glomerular filtration rate and albuminuria: a systematic review. *Adv Ther*. 2021;38(1):180–200. doi:10.1007/s12325-020-01568-8

11. Muiru AN, Charlebois ED, Balzer LB, et al. The epidemiology of chronic kidney disease (CKD) in rural East Africa: a population-based study. *PLoS One*. 2020;15(3):e0229649. doi:10.1371/journal.pone.0229649

12. Kaze AD, Ilior T, Jaar BG, Echoufo-Tegeuji IU. Burden of chronic kidney disease on the African continent: a systematic review and meta-analysis. *BMC Nephrol*. 2018(19):1–12. doi:10.1186/s12882-018-0930-5

13. Eranpoo S, Etanad M, Kazempour S, et al. Diabetes, hypertension, and incidence of chronic kidney disease: is there any multiplicative or additive interaction? *Int J Endocrinol Metab*. 2021;19(1):e101061. doi:10.5812/ijiem.101061

14. Cheung AK, Chang TI, Cushman WC, et al. Executive summary of the KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. *Kidney Int*. 2021;99(3):559–569. doi:10.1016/j.kint.2020.10.026

15. Kalantar-Zadeh K, Jafar TH, Nitsch D, Neuen BL, Perkovic V. Chronic kidney disease. *Lancet*. 2021;398(10302):786–802. doi:10.1016/S0140-6736(21)00519-5

16. Kalantar-Zadeh K, Li PK, Tantisattamo E, et al. Living well with kidney disease by patient and care-partner empowerment: kidney health for everyone everywhere. *Nephron*. 2021;145(3):205–211. doi:10.1159/000513867

17. Naicker S, Jha V. Nephropathy in Africa: forgotten no more. *Kidney Int*. 2020;98(4):804–806. doi:10.1016/j.kint.2020.07.016

18. van Rijn MHC, Alencar de Pinho N, Wetzels JF, van den Brand J, Stengel B. Worldwide disparity in the relation between CKD prevalence and kidney failure risk. *Kidney Int Rep*. 2020;5(12):2284–2291. doi:10.1016/j.ekir.2020.09.040

19. Idris A, Wurie HR, Bertone M, Elinman K, Vital N, Samai M. A scoping study on non-communicable diseases (NCDs) in Sierra Leone. *2018*.

20. World Health Organization. Non-communicable Diseases (NCD) country profiles; 2018. Available from: https://www.who.int/nmh/countries/sle_en.pdf?ua=1. Accessed December 13, 2021.

21. Awad M, Ruzza A, Mirocha J, et al. Prevalence of hypertension in the Gambia and Sierra Leone, western Africa: a cross-sectional study. *Cardiovasc J Afr*. 2014;25(6):269–278. doi:10.5830/cja-2014-058

22. Meehan KA, Banksoki AJ, Tejan E, et al. Hypertension in Bo, Sierra Leone. *WHO steps survey - 2009 - the prevalence of diabetes-related chronic kidney disease from 1990 to 2019*. doi:10.1016/j.ekir.2020.09.040

23. Shirpak MG, Tummalapalli SL, Boulware LE, et al. The case for early identification and intervention of chronic kidney disease: conclusions from a Kidney Disease: improving Global Outcomes (KDIGO) Controversies Conference. *Kidney Int*. 2021;99(1):34–47. doi:10.1016/j.kint.2020.10.012

24. Fiseha T, Ahmed E, Chalie S, Gebreweld A. Prevalence and associated factors of impaired renal function and albuminuria among adult patients admitted to a hospital in Northeast Ethiopia. *Cardiovasc J Afr*. 2014;25(6):269–278. doi:10.5830/cja-2014-058

25. Fiseha T, Ahmed E, Chalie S, Gebreweld A. Prevalence and associated factors of impaired renal function and albuminuria among adult patients admitted to a hospital in Northeast Ethiopia. *PLoS One*. 2021;16(2):e0246509. doi:10.1371/journal.pone.0246509

26. Sierra Leone NCD Poverty Commission. Sierra Leone non-communicable diseases and injuries poverty commission: findings and recommendation; 2020.

27. Ministry of Health and Sanitation. Sierra Leone basic package of essential health services 2015–2020; 2015.

28. Levey AS, Becker C, Inker LA. Glomerular filtration rate and albuminuria for detection and staging of acute and chronic kidney disease in adults: a systematic review. *JAMA*. 2015;313(8):837–846. doi:10.1001/jama.2015.0602
29. Statistics Sierra Leone. 2015 population and housing census; summary of final results; 2016.
30. United Nations Office for the Coordination of Humanitarian Affairs (OCHA) Sierra Leone. Kono district profile; 2015. Available from: https://www.humanitarianresponse.info/en/operations/sierra-leone. Accessed December 13, 2021.
31. Bangura M, Frithauf A, Mhango M, et al. Screening, vaccination uptake and linkage to care for Hepatitis B virus among health care workers in rural Sierra Leone. *Trop Med Infect Dis.* 2021;6(2). doi:10.3390/tropicalmed6020065
32. Kachimanga C, Bangura M, Nyama E, et al. Screening and linkage to care for medical students with Hepatitis B virus infection in Sierra Leone. *Helivyon.* 2020;6(8):e04673. doi:10.1016/j.helivyon.2020.e04673
33. Partners In Health. New Hepatitis B clinic launches in Sierra Leone; 2019. Available from: https://www.who.int/article/new-hepatitis-b-clinic-launches-sierra-leone. Accessed December 13, 2021.
34. Idriess A, Diaconu C, Zou G, Senesi RG, Wurie H, Witter S. Rural–urban health-seeking behaviours for non-communicable diseases in Sierra Leone. *BMJ Global Health.* 2020;5(2):e002024. doi:10.1136/bmjgh-2019-000204
35. Kachimanga C, Dibba Y, Patiño M, et al. Implementation of a non-communicable disease clinic in rural Sierra Leone: early experiences and lessons learned. *J Public Health Policy.* 2021;42:422–438. doi:10.1177/1472139721000304
36. Sumaili EK, Cohen EP, Zinga CV, Krzesinski JM, Pakasa NM, Nseka NM. High prevalence of undiagnosed chronic kidney disease among at-risk population in Kinshasa, the Democratic Republic of Congo. *BMC Nephrol.* 2009;10:18. doi:10.1186/1471-2369-10-18
37. Ladi-Akinyemi TW, Ajayi I. Risk factors for chronic kidney disease among patients at Olabisi Onabanjo University Teaching Hospital in Sagamu, Nigeria: a retrospective cohort study. *Malawi Med J.* 2017;29(2):160–170. doi:10.4314/mmj.v29i2.17
38. Kalyesubula R, Fabian J, Nakanga W, et al. How to estimate glomerular filtration rate in sub-Saharan Africa: design and methods of the African Research into Kidney Diseases (ARK) study. *BMC Nephrol.* 2020;21(1):20. doi:10.1186/s12882-020-1688-0
39. KDIGO. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. *Kidney Int Suppl.* 2013;3(1):5–15.
40. Eastwood JB, Kerry SM, Plange-Rhule J, et al. Assessment of GFR by four methods in adults in Ashanti, Ghana: the need for an eGFR equation for lean African populations. *Nephrol Dial Transplant.* 2010;25(7):2178–2187. doi:10.1093/ndt/gfp765
41. Fabian J, George JA, Etheredge HR, et al. Methods and reporting of kidney function: a systematic review of studies from sub-Saharan Africa. *Clin Kidney J.* 2019;12(6):778–787. doi:10.1093/ckj/sfy089
42. Deckert A, Neuhann F, Kloee C, et al. Assessment of renal function in routine care of people living with HIV on ART in a resource-limited setting in urban Zambia. *PLoS One.* 2017;12(9):e0184766. doi:10.1371/journal.pone.0184766
43. Weir CB, Jan A. BMI classification percentile and cut off points. In: *StatPears [Internet].* Treasure Island (FL): StatPearls Publishing; 2021.
44. HUMAN. Overview of HUMAN. Available from: https://www.human.de/about-human/overview-human/. Accessed December 13, 2021.
45. Peake M, Whiting M. Measurement of serum creatinine–current status and future goals. *Clin Biochem Rev.* 2006;27(4):173–184.
46. Oguejofo F, Kiggundu DS, Bello AK, et al. International Society of Nephrology Global Kidney Health Atlas: structures, organization, and services for the management of kidney failure in Africa. *Kidney Int Suppl.* 2021;11(2):e11–c23. doi:10.1016/j.kisup.2021.01.009
47. Kazee FF, Meto DT, Halle MP, Ngogang J, Kengne AP. Prevalence and determinants of chronic kidney disease in rural and urban Cameroonians: a cross-sectional study. *BMC Nephrol.* 2015;16:117. doi:10.1186/s12882-015-0111-8
48. Kimela Goro K, Desalegn Wolde A, Kerga Dibafa F, et al. Patient awareness, prevalence, and risk factors of chronic kidney disease among diabetes mellitus and hypertensive patients at Jimma University Medical Centre, Ethiopia. *Biomed Res Int.* 2019;2019:2383508. doi:10.1155/2019/2383508
49. Kazee FF, Kengne AP, Magatsing CT, Halle MP, Yiagninii E, Ngku KB. Prevalence and determinants of chronic kidney disease among hypertensive camerounians according to three common estimators of the glomerular filtration rate. *J Clin Hypertens.* 2016;18(5):408–414. doi:10.1111/jch.12781
50. Abd ElHafeez S, Bolignano D, D’Arrigo G, Dounoussi E, Tripepi G, Zoccali C. Prevalence and burden of chronic kidney disease among the general population and high-risk groups in Africa: a systematic review. *BMJ Open.* 2018;8(1):e015069. doi:10.1136/bmjopen-2016-015069
51. Abene EE, Gimba ZM, Edah JO, et al. Blood pressure control and kidney damage in hypertension: results of a three-center cross-sectional study in North Central Nigeria. *Niger J Clin Pract.* 2020;23(11):1590–1597. doi:10.4103/njcp.njcp_271_20
52. Scek SM, Doupa D, Guéye L, Ba I. Chronic kidney disease epidemiology in northern Senegal: a cross-sectional study. *Iran J Kidney Dis.* 2014;8(4):286–291.
53. Bahrey D, Gebremedhin G, Mariye T, et al. Prevalence and associated factors of chronic kidney disease among adult hypertensive patients in Tigray teaching hospitals: a cross-sectional study. *BMC Res Notes.* 2019;12(1):562. doi:10.1186/s13104-019-4610-8
54. George C, Moguego A, Okpechi I, Echouffo-Tcheugui JB, Kengne AP. Chronic kidney disease in low-income to middle-income countries: the case for increased screening. *BMJ Glob Health.* 2017;2(2):e000256. doi:10.1136/bmjgh-2016-000256
55. Hill NR, Fatoba ST, Oke JL, et al. Global prevalence of chronic kidney disease - A systematic review and meta-analysis. *PLoS One.* 2016;11(7):e0158765. doi:10.1371/journal.pone.0158765
56. Mwenda V, Gituku J, Gathecha G, Wambugu BM, Roka ZG, Ong’or WO. Prevalence and factors associated with chronic kidney disease among patients at Olabisi Onabanjo University Teaching Hospital in Sagamu, Nigeria: a retrospective cohort study. *Niger J Clin Pract.* 2019;12(1):562. doi:10.4103/njcp.njcp_271_20
57. Tangkijatkumjai M, Boardman H, Praditpornsilpa K, Walker DM. Association of herbal and dietary supplements with progression and complications of chronic kidney disease: a prospective cohort study. *Nephrology.* 2015;20(10):679–687. doi:10.1111/npj.12531